A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
Sponsor: Sanofi
Listed as NCT06224348, this PHASE3 trial focuses on Dermatitis Atopic and remains completed. Sponsored by Sanofi, it has been updated 18 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
18 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE3
▶ Show 13 earlier versions
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE3
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE3
First recorded
Jan 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Ankara, Turkey (Türkiye) , Antalya, Turkey (Türkiye) , Augsburg, Germany , Bad Bentheim, Germany , Bilbao, Spain , Birmingham, United States , Bologna, Italy , Bordeaux, France , Bountiful, United States and 128 more locations